Eric Schmidt's most recent trade in Revolution Medicines Inc was a trade of 18,400 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 8, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 18,400 | 18,400 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 5,200 | 21,251 (0%) | 0% | 0 | Common Stock | |
| Relmada Therapeutics Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 92,958 | 150,000 | - | - | Stock Option (right to buy) | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 558,094 | 862,439 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 432,738 | 432,738 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 14 Mar 2023 | 35,879 | 304,345 (0%) | 0% | 5.5 | 196,258 | Common Stock |
| Relmada Therapeutics Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 57,042 | 57,042 | - | - | Stock Option (right to buy) | |
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 18,400 | 18,400 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 5,200 | 16,051 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 368,589 | 368,589 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 237,358 | 337,904 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 15 Mar 2022 | 11,469 | 100,546 (0%) | 0% | 7.6 | 87,551 | Common Stock |
| Relmada Therapeutics Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 58,765 | 58,765 | - | - | Stock Option (right to buy) | |
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 12,659 | 12,659 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 3,617 | 10,851 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.22 per share. | 24 May 2021 | 14,897 | 110,994 (0%) | 0% | 18.2 | 271,423 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2021 | 14,897 | 94,703 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 92,365 | 92,365 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 24,866 | 96,097 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.23 per share. | 15 Mar 2021 | 8,053 | 71,231 (0%) | 0% | 38.2 | 307,889 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.40 per share. | 14 Jan 2021 | 11,053 | 1,152,995 (0%) | 0% | 32.4 | 358,151 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.60 per share. | 14 Jan 2021 | 9,851 | 1,172,744 (0%) | 0% | 30.6 | 301,481 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.10 per share. | 14 Jan 2021 | 5,149 | 1,167,595 (0%) | 0% | 31.1 | 160,129 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.69 per share. | 14 Jan 2021 | 3,547 | 1,164,048 (0%) | 0% | 31.7 | 112,393 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.28 per share. | 14 Jan 2021 | 400 | 1,152,595 (0%) | 0% | 33.3 | 13,314 | Common Stock |
| Relmada Therapeutics Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 100,000 | 100,000 | - | - | Options to purchase common stock | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.00 per share. | 16 Nov 2020 | 10,366 | 1,182,595 (0%) | 0% | 33 | 342,078 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.60 per share. | 16 Nov 2020 | 4,634 | 1,192,961 (0%) | 0% | 32.6 | 151,068 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.47 per share. | 15 Oct 2020 | 5,104 | 1,207,491 (0%) | 0% | 39.5 | 201,442 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.07 per share. | 15 Oct 2020 | 4,218 | 1,203,273 (0%) | 0% | 40.1 | 169,011 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.33 per share. | 15 Oct 2020 | 3,479 | 1,199,794 (0%) | 0% | 41.3 | 143,800 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.32 per share. | 15 Oct 2020 | 2,099 | 1,197,695 (0%) | 0% | 42.3 | 88,840 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 43.01 per share. | 15 Oct 2020 | 100 | 1,197,595 (0%) | 0% | 43.0 | 4,301 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.75 per share. | 21 Sep 2020 | 9,889 | 1,217,706 (0%) | 0% | 34.8 | 343,692 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.96 per share. | 21 Sep 2020 | 3,200 | 1,214,506 (0%) | 0% | 36.0 | 115,069 | Common Stock |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 37.04 per share. | 21 Sep 2020 | 1,911 | 1,212,595 (0%) | 0% | 37.0 | 70,783 | Common Stock |